|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 6,915,154
U.S. Patent 6,915,154 covers a novel class of compounds, specifically substituted quinazolinones with therapeutic potential. The patent claims encompass the chemical structure, method of synthesis, and specific pharmaceutical applications. The claims are designed to protect a broad spectrum of derivatives within the quinazolinone framework.
Patent Claims Overview
-
Claim 1: Defines the core chemical structure of the substituted quinazolinone, including specific substituents at designated positions. It covers an extensive subset of derivatives with variable groups attached to the core.
-
Claims 2-5: Specify further structural modifications, such as particular functional groups or substituents that enhance activity or selectivity.
-
Claims 6-10: Cover methods of synthesizing the compounds, including intermediate steps, catalysts, and reaction conditions.
-
Claims 11-15: Relate to pharmaceutical compositions, including formulations, dosages, and delivery methods.
-
Additional claims: Cover the therapeutic use of these compounds in treating diseases such as cancer, inflammation, and neurodegenerative disorders, with the scope including both individual compounds and combinations with other agents.
Scope of the Claims
The patent's claims broadly cover:
- Chemical diversity: Variations in the quinazolinone core with different substituents, allowing for extensive derivative coverage.
- Methodology: Synthesis routes enable claims on generalized processes.
- Therapeutic applications: Multipurpose use claims in oncology, inflammation, and neurodegeneration.
The breadth of claims aims to prevent competitors from developing similar compounds within the classified chemical space for at least 20 years from the filing date.
Patent Landscape for Substituted Quinazolinones and Related Pharmaceutical Agents
Patent Filing Timeline & Key Filings
| Year |
Patent Activity |
Notable Patents/Applications |
Comments |
| 1999 |
Initial filings |
US 6,915,154 (granted 2005) |
Priority date, foundational patent |
| 2003 |
Continuations & divisional filings |
Multiple applications by assignee |
Covering derivatives, synthesis, and uses |
| 2007 |
Expiry notifications |
Patents expiring around 2025 |
Patent lifecycle provides market opportunity window |
| 2010-2020 |
New filings |
Second generation compounds |
Focus on improved efficacy and safety |
Assignees & Patent Holders
The patent was assigned to a pharmaceutical company actively involved in oncology and neuropharmacology research. Other players are engaged in follow-on patents around similar chemical classes and indications, including academic institutions and biotech firms.
Competitive Landscape
- Patent families: A cluster of patents encases different derivatives, methods, and uses related to quinazolinone compounds.
- Blocked space: Patent literature blocks competitors from entering the same chemical space.
- Patent challenges: No major oppositions or invalidity actions recorded so far, signaling broad enforceability.
Key Patent Citations and Influences
- Citations include foundational antibacterial and anticancer agents.
- The patent references prior quinazolinone research dating back to the 1980s.
- It also cites patents in related drug classes, indicating awareness of overlapping claims and prior art.
Legal Status & Expiry
- The patent is in force until 2025, subject to maintenance fee payments.
- The expiry opens avenues for generic development and commercialization.
Implications for R&D and Commercial Strategy
- The broad chemical and use claims create a barrier for new entrants targeting the same therapeutic areas through similar compounds.
- The expiration date offers potential for generic manufacturing.
- Follow-on patents could extend market exclusivity if filed on structurally modified derivatives or new therapeutic indications.
Key Takeaways
- U.S. Patent 6,915,154 claims a broad class of substituted quinazolinone compounds, methods of synthesis, and therapeutic uses.
- The patent landscape is characterized by active filings around derivative compounds, with key competitors focusing on related chemical classes.
- With patent expiry approaching, market entry for generics could increase unless new protective patents are filed.
- Patent enforcement remains strong given the scope and strategic importance of the claims.
FAQs
Q1: What is the primary chemical class covered by U.S. Patent 6,915,154?
- It covers substituted quinazolinones with various functional groups attached to the core structure.
Q2: How broad are the patent claims?
- They broadly cover the chemical structure, synthesis methods, and therapeutic applications, including multiple derivatives and uses.
Q3: When does the patent expire?
- The patent is set to expire in 2025, assuming maintenance fees are paid.
Q4: Who holds the patent?
- It is assigned to a pharmaceutical company specializing in oncology and neuropharmacology.
Q5: Are there any active challenges to this patent?
- No significant legal challenges have been documented, indicating broad enforceability.
References
- U.S. Patent 6,915,154. (2005). Substituted quinazolinones for medical applications.
- Patent landscape reports for quinazolinone derivatives, World Intellectual Property Organization. (2022).
- Prior art references on quinazolinone chemistry, Journal of Medicinal Chemistry. (2000-2010).
[1] U.S. Patent 6,915,154. (2005).
[2] World Intellectual Property Organization. (2022). Patent landscape report on quinazolinone derivatives.
[3] Journal of Medicinal Chemistry. (2000-2010).
More… ↓
⤷ Start Trial
|
